UBS Group’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-660
| Closed | -$6K | – | 8575 |
|
|
2018
Q2 | $6K | Buy |
660
+415
| +169% | +$3.73K | ﹤0.01% | 7443 |
|
|
2018
Q1 | $2K | Sell |
245
-3,450
| -93% | -$29K | ﹤0.01% | 7600 |
|
|
2017
Q4 | $18K | Buy |
3,695
+3,570
| +2,856% | +$17.4K | ﹤0.01% | 6650 |
|
|
2017
Q3 | $1K | Sell |
125
-2,058
| -94% | -$9.66K | ﹤0.01% | 7645 |
|
|
2017
Q2 | $11K | Buy |
2,183
+2,040
| +1,427% | +$9.13K | ﹤0.01% | 6747 |
|
|
2017
Q1 | $1K | Sell |
143
-3,791
| -96% | -$19.2K | ﹤0.01% | 7528 |
|
|
2016
Q4 | $22K | Sell |
3,934
-695
| -15% | -$3.81K | ﹤0.01% | 6470 |
|
|
2016
Q3 | $25K | Buy |
4,629
+1,129
| +32% | +$7.47K | ﹤0.01% | 6122 |
|
|
2016
Q2 | $25K | Hold |
3,500
| – | – | ﹤0.01% | 6131 |
|
|
2016
Q1 | $23K | Sell |
3,500
-7,948
| -69% | -$58.5K | ﹤0.01% | 6110 |
|
|
2015
Q4 | $118K | Buy |
11,448
+4,733
| +70% | +$54.9K | ﹤0.01% | 5084 |
|
|
2015
Q3 | $79K | Sell |
6,715
-1,486
| -18% | -$16.4K | ﹤0.01% | 5428 |
|
|
2015
Q2 | $75K | Buy |
8,201
+2,987
| +57% | +$22.6K | ﹤0.01% | 5646 |
|
|
2015
Q1 | $33K | Buy |
5,214
+134
| +3% | +$829 | ﹤0.01% | 6469 |
|
|
2014
Q4 | $28K | Buy |
+5,080
| New | +$29.6K | ﹤0.01% | 7200 |
|
UBS Group's JNP Position: Q3 2018 in Review
UBS Group sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 660 shares — an estimated $6K sold.
UBS Group first reported a position in JNP in Q4 2014 and held it in 15 quarters. The position peaked at $118K in Q4 2015. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- UBS Group reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- UBS Group sold 660 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $6K.
- UBS Group first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q4 2014 and held it in 15 quarters.
- UBS Group's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $118K in Q4 2015.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.